SLC1A2 and epilepsy: In summary, p38 MAPK, Glu and EAAT2 appear to be associated with epilepsy, and SB203580 competitively binds to ATP binding sites for the purpose of inhibiting p38MAPK, thereby effectively inhibiting some signal transduction induced by some inflammatory factors.